Exome sequencing reveals novel and recurrent mutations with clinical impact in blastic plasmacytoid dendritic cell neoplasm

Autores: Menezes, J.; Acquadro, F.; Wiseman, M.; Gómez-López, G.; Salgado, R. N.; Talavera-Casañas, J. G.; Buño, I.; Cervera, J. V.; Montes-Moreno, S.; Hernández-Rivas, J. M.; Ayala, R.; Calasanz Abinzano, María José; Larráyoz Ilundáin, María José; Brichs, L. F.; González-Vicent, M.; Pisano, D. G.; Piris, M. A.; Álvarez, S.; Cigudosa, J. C.
Título de la revista: LEUKEMIA
ISSN: 0887-6924
Volumen: 28
Número: 4
Páginas: 823 - 829
Fecha de publicación: 2014
Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a very rare disease that currently lacks genomic and genetic biomarkers to assist in its clinical management. We performed whole-exome sequencing (WES) of three BPDCN cases. Based on these data, we designed a resequencing approach to identify mutations in 38 selected genes in 25 BPDCN samples. WES revealed 37-99 deleterious gene mutations per exome with no common affected genes between patients, but with clear overlap in terms of molecular and disease pathways (hematological and dermatological disease). We identified for the first time deleterious mutations in IKZF3, HOXB9, UBE2G2 and ZEB2 in human leukemia. Target sequencing identified 29 recurring genes, ranging in prevalence from 36% for previously known genes, such as TET2, to 12-16% for newly identified genes, such as IKZF3 or ZEB2. Half of the tumors had mutations affecting either the DNA methylation or chromatin remodeling pathways. The clinical analysis revealed that patients with mutations in DNA methylation pathway had a significantly reduced overall survival (P= 0.047). We provide the first mutational profiling of BPDCN. The data support the current WHO classification of the disease as a myeloid disorder and provide a biological rationale for the incorporation of epigenetic therapies for its treatment.